Robert Califf On Publishing Trial Data, FDA Standard-Setting, Patient Advocacy
This article was originally published in The Tan Sheet
The FDA commissioner nominee talks with FasterCures Director Margaret Anderson about what he has learned since joining the agency.
You may also be interested in...
With the meetings available on television, access can be assured for just about everyone, and the US FDA can avoid another gut punch to its credibility.
Japan approves a batch of new products and indications, including Daiichi Sankyo's Enhertu in a high-need indication after a rapid review and Takeda's Zejula, which will be made available to selected patients before its reimbursement listing.
Public Company Edition: Outside the US, Zai Lab raised more in its recent Hong Kong initial public offering – $766.4m – than PMV, Prelude, Taysha, Graybug and Greenwich combined. Also, Gilead priced debt to fund its $21bn Immunomedics buy and ADC Therapeutics raised $204m.